Day: September 12, 2022

Figure 1: Plan map of São Francisco target, locating high-grade rock samples, Trado® auger holes and soil sampling sites (assays pending). Figure 1: Plan map of São Francisco target, locating high-grade rock samples, Trado® auger holes and soil sampling sites (assays pending).Figure 2: Photographs of high-grade chromitite and ultramafic rock samples from São Francisco target. Figure 2: Photographs of high-grade chromitite and ultramafic rock samples from São Francisco target: A – Sample 103250, 13.69 g/t 2PGE+Au; B – Sample 103243, 12.18 g/t 2PGE+Au; C – Sample 103241, serpentinized peridotite outcrop, 1.15 g/t 2PGE+Au and Trado® auger ‘core’ (D) showing well preserved serpentinized peridotite in hole AD22SF12 (assays pending).VANCOUVER, British Columbia, Sept. 12, 2022 (GLOBE NEWSWIRE) — ValOre Metals Corp. (“ValOre”; TSX‐V:...

JERUSALEM, Sept. 12, 2022 (GLOBE NEWSWIRE) — Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and therapeutic proteins, today announced that the Company will present and host 1×1 meetings at the upcoming H.C. Wainwright 24th Annual Global Investment Conference.Presentation Date: Wednesday, September 14, 2022Time: 3:30 PM ETPresenter: Miranda Toledano – CEOConference Website https://hcwevents.com/globalconference/About Entera BioEntera is a leader in the development of orally delivered macromolecules therapeutics including peptides and other therapeutic proteins, for use in areas with significant unmet medical need where adoption of injectable therapies is limited due to cost, convenience and compliance challenges for patients. The Company’s...

Investor Teleconference and Webcast Scheduled Tomorrow, September 13, 2022, at 7:30 a.m. EDT CAMBRIDGE, Mass., Sept. 12, 2022 (GLOBE NEWSWIRE) — Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is biologically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™ for the treatment of cancer and autoimmune diseases, today announced that the Company plans to provide a strategic update and host an investor teleconference and webcast on Tuesday, September 13, 2022, at 7:30 a.m. EDT. Investor Teleconference & Webcast An audio webcast will be available on the Events and Presentations page within the Investors and Media section of the Rubius Therapeutics website and can be directly accessed here. An archived webcast will be accessible...

Provides Favorable Access to a New $500 Million Market for the Treatment of Refractory Diabetic and Venous Ulcers for EPIFIX – the First and Only Amniotic Tissue Product Approved for Use in Japan MARIETTA, Ga., Sept. 12, 2022 (GLOBE NEWSWIRE) — MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), a transformational placental biologics company, today announced that the Japanese Ministry of Health, Labour and Welfare (JMHLW) approved reimbursement of EPIFIX® to treat refractory or hard-to-heal lower extremity diabetic and venous ulcers. The Company is in the last stages of preparing for full product launch, anticipated in the fourth quarter. The Company estimates the Japanese total addressable market associated with the scope of the JMHLW reimbursement decision to be approximately $500 million based on a recently completed...

GRANTS, N.M., Sept. 12, 2022 (GLOBE NEWSWIRE) — Bright Green Corporation (NASDAQ: BGXX) (“Bright Green” or “the Company”), one of the very few companies selected by the U.S. government to grow, manufacture, and sell, legally under federal and state laws, cannabis and cannabis-related products for research, pharmaceutical applications and affiliated export, today announced the closing of its previously announced private placement of common stock and warrants. The Company sold 9,523,810 shares of common stock and warrants to purchase up to 9,523,810 shares of common stock, at a purchase price of $1.05 per share and accompanying warrant. The warrants are immediately exercisable from the date of issuance at an initial exercise price of $1.05 per share, subject to adjustments as set forth therein, and will expire five years from the...

– With current cash and projected revenue, offering is expected to fund operations to profitability CAMBRIDGE, Mass., Sept. 12, 2022 (GLOBE NEWSWIRE) — Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that it intends to offer, subject to market and other conditions, $1.0 billion aggregate principal amount of convertible senior unsecured notes that will mature on September 15, 2027, unless earlier redeemed, repurchased or converted. The notes will be offered and sold only to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Rule 144A offering”). Sarepta also expects to grant the initial purchasers of the notes an option to purchase up to an additional $150 million aggregate...

Nano Magic Holdings, Inc. Nano Magic LLC, announce the launch of two new products through its Canadian Distribution Partner, Curve Distribution, into Canadian retailer, Walmart Canada.Nano Magic Holdings, Inc. Nano Magic LLC, announce the launch of two new products through its Canadian Distribution Partner, Curve Distribution, into Canadian retailer, Walmart Canada.MADISON HEIGHTS, Mich., Sept. 12, 2022 (GLOBE NEWSWIRE) — Nano Magic LLC, a wholly owned subsidiary of Nano Magic Holdings, Inc. (OTCMKT: NMGX) (“Nano Magic” or the “Company”), a leader in nanotechnology-powered cleaning, protection and anti-fog solutions is pleased to announce the launch of two new products through its Canadian Distribution Partner, Curve Distribution, into Canadian retailer, Walmart Canada. Nano Magic entered into a partnership with Calgary-based...

BRADENTON, Fla., Sept. 12, 2022 (GLOBE NEWSWIRE) — First Watch Restaurant Group, Inc. (NASDAQ: FWRG) (“First Watch” or “the Company”), the Daytime Dining concept serving breakfast, brunch and lunch, today announced that certain stockholders of the Company (the “Selling Stockholders”) intend to offer 4,500,000 shares of the Company’s common stock, par value $0.01 per share (the “Common Stock”), in an underwritten secondary public offering. The Selling Stockholders intend to grant the underwriters a 30-day option to purchase up to an additional 675,000 shares of Common Stock at the public offering price, less underwriting discounts and commissions. The offering consists entirely of secondary shares to be sold by the Selling Stockholders. The Selling Stockholders will receive all of the proceeds from the offering. BofA Securities,...